Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study

Conclusion: Empagliflozin initiation was associated with a significantly reduced risk of ACM, HHF, CVM, and ESRD compared with initiation of DPP-4i in patients with T2D when examining routine clinical practice data from Nordic countries.

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Gisle Langslet, Thomas Nyström, Dorte Vistisen, Bendix Carstensen, Emilie Toresson Grip, Paula Casajust, Giorgi Tskhvarashvili, Fabian Hoti, Riho Klement, Kristina Karlsdotter, Mikko Tuovinen, Anne Pernille Ofstad, Maria Lajer, Christina Shay, Lisette Koeneman, Soulmaz Fazeli Farsani, Leo Niskanen, Sigrun Halvorsen
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Wiley 2024-01-01
Σειρά:	Journal of Diabetes Research
Διαθέσιμο Online:	http://dx.doi.org/10.1155/2024/6142211
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!